Skip to content

Cervical Facet Injection of Corticosteroids for the Management of Cervicobrachialgia

Cervical Facet Injection of Corticosteroids for the Management of Cervicobrachialgia : Protocol for a Randomized Pilot Study

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07084285
Acronym
APICALE
Enrollment
70
Registered
2025-07-24
Start date
2026-01-31
Completion date
2028-05-31
Last updated
2025-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervicobrachial Neuralgia

Keywords

Neuralgia, cervicobrachialgia, cervicobrachial neuralgia, Foraminal conflict, Posterior intra-articular injection, Cervical spinal injection et corticosteroid

Brief summary

The main objective is to evaluate the efficacy of a single posterior intra-articular injection of dexamethasone on radicular pain (RP) at 1 month in the treatment of uncomplicated chronic cervicobrachial neuralgia (CBN) in adults, resistant to well-conducted first-line medical treatment.

Detailed description

Cervicobrachial Neuralgia (CBN) is a common condition caused by the compression of a nerve root (C5, C6, C7, or C8) in the cervical spine. In 10% of cases, the duration of symptoms exceeds 3 months, at which point it is considered chronic. Two main etiologies are distinguished : * Soft disc herniation, * uncodiscarthrotic foraminal stenosis. The pathophysiology involves both mechanical compression and local inflammation. The initial management is typically medical, provided if there are no signs of severity. If medical treatment fails or if signs of severity are present, surgical intervention is required. The role of corticosteroid injections in the therapeutic strategy in France remains controversial. Literature on the efficacy of cervical spinal injections is heterogeneous and limited, the safety of such injections is debated, and product availability is restricted. We hypothesize that posterior intra-articular dexamethasone injection would be effective for radicular pain resistant to first-line medical treatment.

Interventions

DRUGDexamethasone

A single 4mg (1mL) dexamethasone injection via the posterior intra-articular route, under CT guidance

1 mL isotonic saline solution, injectable, for a single posterior intra-articular injection, under CT guidance.

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years, * Unilateral monoradicular cervicobrachial neuralgia (CBN), * Predominant radicular pain, with a Radicular Visual Analog Scale (VAS) score ≥ 40/100, * Imaging (CT or preferably MRI) performed within the last 6 months, * Foraminal conflict at one level on imaging (CT or preferably MRI) performed within the last 6 months, confirmed by a senior investigator trained in the study, * Failure of medical treatment that included at least one analgesic (level I to III) and one oral anti-inflammatory (NSAIDs and/or corticosteroids) for at least 7 consecutive days within the last 3 months, * Discontinuation of oral anti-inflammatory drugs (NSAIDs and/or corticosteroids) 24 hours prior to randomization, * Current episode duration ≥ 3 months, * Negative pregnancy test on the day of the procedure for premenopausal female patients, * Patients of childbearing age must have reliable contraception for the duration of the study, * Absence of biological inflammatory syndrome, thrombocytopenia, or coagulation disorders on the day of the procedure, * Patient capable of providing written informed consent prior to participating in the study.

Exclusion criteria

* Inability to speak, read, or write French fluently, * Patient under guardianship or custody, or deprived of liberty, * No affiliation with social security, * Neurological signs of severity (clinical motor deficit ≤ 3/5, pyramidal irritation signs, or cervical spinal cord edema on MRI), * Non-concordant imaging within the last 6 months (absence of conflict, contralateral conflict, or ipsilateral conflict not immediately adjacent), confirmed by a senior investigator trained in the study, * Recent cervical spine injection (\< 3 months), * Foraminal conflict at more than 2 levels, * History of cervical spine surgery within the last 12 months or scheduled surgery in this indication within 6 months, * Secondary CBN (traumatic, infectious, neoplastic, or inflammatory etiology), * Contraindication to fluoroscopy-guided injection (contrast agent allergy, allergy or contraindication to dexamethasone administration), * Pregnant women, * Ongoing participation in another therapeutic trial or interventional research study, * Patient suspected of non-compliance with the study protocol.

Design outcomes

Primary

MeasureTime frameDescription
Radicular pain (RP) assessed using a simple self-administered numeric rating scaleMonth1Simple self-administered numeric rating scale, ranging from 0 (no pain) to 100 (maximum pain), over the 48 hours preceding the 1-month visit assessment.

Secondary

MeasureTime frameDescription
The use of analgesics (levels 1, 2, or 3) since the last visitDay 15, Month1, Month2, Month3Self-administered 4-level scale (never, several times a month, several times a week, daily) at Day 15, month1, month2 and 3 months post-injection.
Cervical pain (numeric rating scale, self-administered)Day 15, Month1, Month2, Month3Numeric rating scale, self-administered, ranging from 0 to 100 over the 48 hours preceding Day 15, 1 month, 2 month and 3 month
Neck Disability Index (NDI) scoreMonth1 and Month3Self-administered functional scale, ranging from 0 to 50 at Month 1 and Month 3
The occurrence of adverse events (AEs) and serious adverse events (SAEs)Day15, Month1, Month2, Month3
Self-administered EQ5D quality of life scaleMonth1 and Month3
Radicular pain (RP) assessed using a simple self-administered numeric rating scaleOver the 48 hours preceding the Day 15, the 2-month and the 3-month visits assessment.Simple self-administered numeric rating scale, ranging from 0 (no pain) to 100 (maximum pain), over the 48 hours preceding the visit assessment
Professional statusMonth1 and Month3Self-reported : employed, on sick leave, disabled, unemployed, inactive, retired at Month 1 and Month 3

Countries

France

Contacts

Primary ContactCamille DASTE, MD,PhD
camille.daste@aphp.fr01 58 41 51 38
Backup ContactLaetitia PEAUDECERF, PhD
laetitia.peaudecerf@aphp.fr01 58 41 12 13

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026